Items where authors include "Combe, B"

Export as [feed] Atom [feed] RSS
Number of items: 8.

Article

Aletaha, D, Kerschbaumer, A, Kastrati, K et al. (41 more authors) (2022) Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases. ISSN 0003-4967

Combe, B, Landewe, R, Daien, CI et al. (20 more authors) (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases, 76 (6). pp. 948-959. ISSN 0003-4967

Smolen, JS, Landewé, R, Bijlsma, J et al. (46 more authors) (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76 (6). pp. 960-977. ISSN 0003-4967

Combe, B, Furst, DE, Keystone, EC et al. (5 more authors) (2016) Certolizumab Pegol Remains an Equally Efficacious Treatment of Rheumatoid Arthritis Over a Range of Background Methotrexate Regimens. Arthritis Care and Research, 68 (3). pp. 299-307. ISSN 2151-464X

Smolen, JS, Breedveld, FC, Burmester, GR et al. (40 more authors) (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. British Journal of Sports Medicine, 75 (1). pp. 3-15. ISSN 0306-3674

Smolen, JS, Breedveld, FC, Burmester, G et al. (40 more authors) (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 75 (1). pp. 3-15. ISSN 0003-4967

Buch, MH orcid.org/0000-0002-8962-5642, Silva-Fernandez, L, Carmona, L et al. (18 more authors) (2015) Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Annals of the Rheumatic Diseases, 74 (6). pp. 963-969. ISSN 0003-4967

Proceedings Paper

Genovese, M, Helliwell, P, Combe, B et al. (6 more authors) (2018) Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study. In: Journal of Rheumatology. 73rd Annual Meeting of The Canadian-Rheumatology-Association (CRA), 21-24 Feb 2018, Vancouver, Canada. Journal of Rheumatology Publishing Co., Ltd. , p. 996.

This list was generated on Sat May 4 12:03:02 2024 BST.